Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
Launched by ASTRAZENECA · Feb 19, 2010
Trial Information
Current as of April 28, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with painful osteoarthritis of the knee.
- • The pain from the knee must exceed pain experienced from any other condition.
- • Patients must be willing and able to discontinue all current analgesic treatment.
- Exclusion Criteria:
- • Any other form of arthritis than osteoarthritis.
- • Presence of neuropathic pain, or fibromyalgia, or wide spread chronic pain not related to osteoarthritis.
- • Significant abnormalities on the clinical examination that may interfere with the study or present a safety risk to the patient, as judged by the investigator.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London Bridge, Greater London, United Kingdom
Patients applied
Trial Officials
Rolf Karlsten
Study Director
AstraZeneca RD Södertälje
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials